Newly-Created Center on Integrated Global Biomedical Sciences Is Part of the University's Innovation in Technology Initiatives
ALACHUA, FL -- (Marketwired) -- 07/07/16 -- CTD Holdings, Inc. (OTCQB: CTDH), a biotechnology company that develops cyclodextrin-based products for the treatment of disease, today announced that Dr. Sharon H. Hrynkow, Senior Vice President for Medical Affairs and Co-Chair of CTD's Scientific Advisory Board, has joined the advisory board of the newly-launched Center for Integrated Global Biomedical Sciences at The State University of New York, University at Buffalo. The Center, led by Professor Gene Morse, Pharm. D., of the School of Pharmacy and Pharmaceutical Sciences, will address global health challenges through pharmacologic research and drug and vaccine development.
"Dr. Hrynkow's commitment to the scientific community is unwavering, as this appointment well demonstrates," said N. Scott Fine, CTD Chairman and CEO. "We congratulate Dr. Hrynkow and fellow advisors on working to assist the University at Buffalo with this impressive program."
Center Director Dr. Morse said: "Having worked with Dr. Hrynkow for decades in building scientific and health capacity in resource-poor nations, I am excited to once again have the opportunity to collaborate with her. Our center will benefit immensely from her wisdom and insights on many levels."
Dr. Hrynkow is honored to be an advisor to the University's new Center. "Global health encompasses diseases and conditions such as HIV/AIDS, cardiovascular disease, brain disorders and cancers that affect millions of people, as well as rare diseases whose solutions will only be found through international cooperation," said Dr. Hrynkow. "I look forward to advising the Center on its programming opportunities for the full spectrum of health challenges facing the global community."
About the Company:
CTD Holdings, Inc. is a biotechnology company that develops cyclodextrin-based products for the treatment of disease. The company's Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is used to treat Niemann-Pick Type C, a rare and fatal genetic disease. Additional indications for the active ingredient in Trappsol® Cyclo™ are in development. For additional information, visit the company's website: www.ctd-holdings.co
Safe Harbor Statement:
This press release contains "forward-looking statements" about the company's current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as "anticipates," "believes" and "expects" or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from what is expressed in, or implied by, these statements. The factors which may influence the company's future performance include the company's ability to obtain additional capital to expand operations as planned, success in achieving regulatory approval for clinical protocols, enrollment of adequate numbers of patients in clinical trials, unforeseen difficulties in showing efficacy of the company's biopharmaceutical products, success in attracting additional customers and profitable contracts, and regulatory risks associated with producing pharmaceutical grade and food products. These and other risk factors are described from time to time in the company's filings with the Securities and Exchange Commission, including, but not limited to, the company's reports on Forms 10-K and 10-Q. Unless required by law, the company assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.
Source: CTD Holdings, Inc.
Source: CTD Holdings, Inc.